Brobust® is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
WARNINGS AND PRECAUTIONS:
LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS B.
The concomitant use of Brobust and P-gp inducers (e.g., rifampin, St. John’s wort) may significantly decrease ledipasvir and sofosbuvir plasma concentrations and may lead to a reduced therapeutic effect of Brobust. Therefore, the use of Brobust with P-gp inducers (e.g., rifampin or St. John’s wort) is not recommended.
The use of Brobust with other products containing sofosbuvir is not recommended.
Sofalvi® (sofosbuvir) 400 mg is a nucleotide analog NS5B polymerase inhibitor for the treatment of chronic hepatitis C (CHC) as a component of a combination antiviral treatment regimen. Sofalvi efficacy has been established in subjects with HCV genotype 1, 2, 3 or 4 infection, Inc luding those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection. The following points should be considered when initiating treatment with Sofalvi:
Monotherapy of Sovaldi is not recommended for treatment of CHC.
Treatment regimen and duration are dependent on both viral genotype and patient population.
Treatment response varies based on baseline host and viral factors.
CONTRAINDICATIONS: Sofalvi combination treatment with ribavirin or with peginterferon alfa plus ribavirin is contraindicated in women who are pregnant or may become pregnant and men whose female partners are pregnant because of the risk for birth defects and fetal death associated with ribavirin. Contraindications to peginterferon alfa and ribavirin also apply to Sofalvi combination treatment. Refer to the prescribing information of peginterferon alfa and ribavirin for a list of their contraindications.